Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant

NCT03807063 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Insufficient funding

Conditions

Acute Bilineal Leukemia
Myelodysplastic/Myeloproliferative Neoplasm
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
Myeloproliferative Neoplasm
Recurrent Acute Biphenotypic Leukemia
Recurrent Acute Lymphoblastic Leukemia
Recurrent Acute Myeloid Leukemia
Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
Recurrent Chronic Lymphocytic Leukemia
Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Recurrent Chronic Myelomonocytic Leukemia
Recurrent Myelodysplastic Syndrome

Interventions

BIOLOGICAL: Rivogenlecleucel
DRUG: Rimiducid

Sponsor

Fred Hutchinson Cancer Center

Collaborators

[object Object]
[object Object]